Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent.
Description: Measured by RECIST 1.1Measure: Objective response rate Time: 12 weeks
Single Group Assignment
There is one SNP
4. Radiological disease progression following at least one prior EGFR TKI. 5. Documented EGFR mutation known to be associated with EGFR TKI sensitivity (also including T790M). --- T790M ---